Xencor Stock Price, News & Analysis

Xencor (NASDAQ:XNCR) reported Q3 2024 financial results with revenues of $10.7 million, down from $59.2 million in Q3 2023. The company posted a net loss of $45.1 million, or $(0.71) per share. Cash position stood at $754.3 million after raising $201.3 million through a public offering. R&D expenses decreased to $58.2 million from $64.9 million year-over-year. The company highlighted progress in its clinical pipeline, including XmAb942 entering Phase 1 trials and partner Amgen advancing xaluritamig to Phase 3 for prostate cancer. Xencor expects to end 2024 with $690-710 million in cash, funding operations into 2028.

Xencor (NASDAQ: XNCR) has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, a high-potency extended half-life anti-TL1A antibody for inflammatory bowel disease. The Phase 1/2 randomized, double-blind, placebo-controlled study will be conducted in three parts: Phase 1 Part A for single-ascending dose cohorts, Part B for repeat doses in healthy volunteers, and Phase 2 Part C for ulcerative colitis patients. Initial data is expected in the first half of 2025. The company believes XmAb942's properties may offer improved clinical benefits and more convenient dosing compared to other anti-TL1A antibodies in development.

Xencor (NASDAQ: XNCR) has announced preclinical data on XmAb942, a high-potency, extended half-life anti-TL1A antibody for inflammatory bowel diseases. The data will be presented at UEG Week in Vienna. XmAb942 aims to be a best-in-class next-generation anti-TL1A antibody, offering superior potency and less frequent dosing compared to first-generation antibodies.

Key points:

• First subject dosing in Phase 1 healthy volunteer study expected in Q4 2024
• Initial data from single-ascending dose portion anticipated in H1 2025
• Preclinical data shows comparable or superior in vitro potency to first-generation anti-TL1A antibodies
• 23-day half-life in non-human primates, potentially supporting 8-12 week dosing in humans

Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and other serious diseases, has announced an upcoming change to its Board of Directors. Dagmar Rosa-Bjorkeson, who has served as a director since 2019, will not seek reelection at the 2025 Annual Meeting of Stockholders. Rosa-Bjorkeson plans to pursue another business opportunity.

Xencor is actively recruiting additional Board members with complementary skillsets. The company's CEO, Bassil Dahiyat, Ph.D., expressed gratitude for Rosa-Bjorkeson's contributions to the Board and its audit and nominating and governance committees, particularly her strategic guidance in advancing programs and rebalancing the company's portfolio.

Xencor (XNCR) has successfully closed its public offering, raising approximately $201.3 million in gross proceeds. The offering included 8,093,712 shares of common stock at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. The underwriters fully exercised their option to purchase additional shares. Xencor plans to use the net proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering was made through an automatic shelf registration statement, with Leerink Partners, Raymond James, and RBC Capital Markets acting as joint book-running managers.

Xencor (XNCR) has priced its public offering of common stock and pre-funded warrants, aiming to raise $175 million. The offering includes 6,635,112 shares at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. Underwriters have a 30-day option to purchase up to 1,458,600 additional shares. The clinical-stage biopharmaceutical company plans to use the proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is expected to close around September 12, 2024, subject to customary conditions.

Xencor (Nasdaq: XNCR), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of shares. Leerink Partners, Raymond James, and RBC Capital Markets are acting as joint book-running managers, with Wedbush PacGrow as co-manager.

The company plans to use the net proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is being made through an automatic shelf registration statement on Form S-3, with a preliminary prospectus supplement to be filed with the SEC.

Xencor, Inc. (NASDAQ: XNCR) announced four new XmAb® programs for treating autoimmune diseases and provided updates on early-stage oncology programs. Key highlights include:

1. XmAb942: Phase 1 study for IBD to start Q4 2024, with data expected H1 2025.
2. Plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3): To be evaluated for autoimmune diseases, with studies starting in 2025.
3. XmAb819 (ENPP3 x CD3): Showing encouraging clinical activity in advanced clear cell renal cell carcinoma.
4. XmAb808 (B7-H3 x CD28): Demonstrating PSA declines in metastatic castration-resistant prostate cancer patients.

The company aims to leverage its protein engineering strengths to increase clinical success opportunities.

Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has announced a Research & Development Webcast and Conference Call scheduled for Monday, September 9, 2024, at 8:00 a.m. ET. The event will introduce new XmAb® programs for treating autoimmune diseases and provide updates on oncology programs, including:

• XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma
• XmAb808 (B7-H3 x CD28) for advanced solid tumors

The webcast can be accessed through the Investors section of Xencor's website. A recording will be available for at least 30 days after the event.